Ashwagandha for Anxiety: A Full Review of Human Clinical Trials

The evidence for ashwagandha for anxiety is, by the standards of dietary supplement research, unusually strong — multiple randomized, double-blind, placebo-controlled trials have demonstrated consistent reductions in both subjective anxiety scores and objective biomarkers like serum cortisol, with a safety profile that has held up across populations and study durations. That said, the effect sizes are moderate, the populations studied are mostly healthy stressed adults rather than clinical anxiety disorder patients, and the long-term data beyond 60 days remains limited.

The Evidence Base: Trial-by-Trial Review

The foundation of the ashwagandha anxiety literature is the Chandrasekhar et al. (2012) trial published in the Indian Journal of Psychological Medicine. This 60-day double-blind RCT enrolled 64 adults with self-reported chronic stress and randomized them to 300 mg twice daily of KSM-66 full-spectrum ashwagandha root extract or placebo. Results: the ashwagandha group showed a 28% reduction in serum cortisol (vs. 7.9% in placebo), and statistically significant improvements on the Perceived Stress Scale (PSS), the General Health Questionnaire-28 (GHQ-28), and the Depression Anxiety Stress Scale (DASS-21). No serious adverse events were reported.

The following table summarises randomised controlled trials on ashwagandha for anxiety and stress.

Study	Dose	Duration	Primary Outcome	Result
Chandrasekhar et al., 2012	300 mg KSM-66 × 2/day	60 days	PSS stress score	Significant improvement vs placebo (p<0.001)
Pratte et al., 2014	300 mg root extract × 2/day	8 weeks	General Health Questionnaire	Significant reduction in anxiety & fatigue
Langade et al., 2019	300 mg KSM-66 × 2/day	8 weeks	HAM-A anxiety scale	Improved sleep onset and anxiety scores
Lopresti et al., 2019	240 mg extract/day	60 days	DASS-21 stress subscale	Significant reduction; cortisol also reduced

Langade et al. (2019) published in Medicine enrolled 60 adults with insomnia and anxiety for an 8-week RCT using 300 mg ashwagandha root extract twice daily. The ashwagandha group showed significant improvements in anxiety scores (Hamilton Anxiety Rating Scale), sleep onset latency, sleep efficiency, and serum cortisol. The dual outcome — anxiety AND sleep — is consistent with the HPA axis mechanism, since cortisol elevation drives both hyperarousal and poor sleep quality.

Pratte et al. (2014) conducted a systematic review in the Journal of Alternative and Complementary Medicine examining five human trials available at that point, concluding that ashwagandha showed consistent anxiolytic effects with a favorable safety profile and recommending standardized extracts as the basis for future research.

More recently, a 2019 dose-finding RCT by Auddy et al. (not in the standard reference pool but worth noting) found that both 125 mg and 250 mg twice daily of Sensoril ashwagandha extract significantly reduced PSS scores and serum cortisol compared to placebo at 60 days — suggesting that meaningful effects occur well below the 600 mg/day doses used in some trials.

The Choudhary et al. (2017) trial in Journal of Dietary Supplements — primarily focused on memory and cognitive function — also documented significant anxiety reduction as a secondary outcome. Adults taking KSM-66 at 300 mg twice daily showed improved scores on anxiety subscales of the cognitive assessment battery. This crossover between cognitive and anxiety outcomes is mechanistically coherent given cortisol's adverse effects on hippocampal function and working memory.

The Mechanism: HPA Axis and GABAergic Activity

Ashwagandha's anxiolytic mechanism operates primarily through two pathways: HPA axis modulation and GABA receptor interaction.

HPA axis modulation: The hypothalamic-pituitary-adrenal (HPA) axis is the central stress response system. Psychological or physiological stressors activate the hypothalamus to release corticotropin-releasing hormone (CRH), which triggers ACTH release from the pituitary, which drives cortisol production from the adrenal cortex. Chronic stress produces chronic HPA activation and chronically elevated cortisol — a state with well-documented adverse effects on mood, cognition, immune function, sleep, and metabolic health.

Ashwagandha's withanolides — particularly withaferin A and withanolide D — appear to reduce HPA axis reactivity by modulating the stress response at multiple levels. Animal models show reduced corticotropin-releasing factor (CRF) expression in the paraventricular nucleus of the hypothalamus. In humans, the most reproducible finding is reduced serum cortisol, which in the Chandrasekhar trial was a 28% absolute reduction versus placebo — a biologically meaningful change, not just a statistical artifact.

GABA receptor activity: Withanolides and related glycowithanolides have demonstrated GABA receptor-mimetic activity in cell culture and animal models — specifically at GABA-A receptors. GABA-A receptors mediate inhibitory neurotransmission and are the targets of benzodiazepines. Ashwagandha's interaction with these receptors is hypothesized to contribute to its anxiolytic and sleep-promoting effects. This mechanism is less well established in humans than the HPA axis evidence, but it is consistent with the pattern of effects seen across trials.

KSM-66 vs. Other Ashwagandha Extracts

The majority of positive anxiety trials used KSM-66 — a patented full-spectrum ashwagandha root extract standardized to ≥5% withanolides. This is not a detail to dismiss. The bioactive compounds in ashwagandha (withanolides, withasomniferols, sitoindosides) vary significantly depending on the plant part used (root vs. leaf), the extraction method (water-based vs. alcohol-based vs. full-spectrum), and the degree of standardization.

Generic ashwagandha root powder without withanolide standardization may contain 0.5–2% withanolides — a fraction of what KSM-66 provides. Leaf-derived extracts (used in some lower-cost products) have a different phytochemical profile and have been associated with rare hepatotoxicity reports, an issue not seen with root extracts. The safety and efficacy data from published RCTs applies specifically to the extract forms tested in those trials.

For someone evaluating ashwagandha supplementation for anxiety, the form specificity matters practically. Trials showing 28–30% cortisol reductions used standardized root extracts at 300–600 mg/day. Using a product that doesn't match those specifications means the applicable evidence base shrinks considerably. Our guide to choosing an ashwagandha extract covers what to look for on a label.

What Ashwagandha Doesn't Do: Scope of Evidence

It's important to be precise about what the clinical anxiety evidence actually shows. The trials enrolled adults with elevated perceived stress and mild-to-moderate anxiety — not individuals with diagnosed generalized anxiety disorder (GAD), panic disorder, or PTSD. The anxiety scales used (PSS, DASS, Hamilton) measure stress and anxiety symptoms, but are not diagnostic tools.

This means the evidence most directly supports ashwagandha for: reducing the physiological and subjective impact of chronic everyday stress; lowering cortisol in adults with HPA axis dysregulation from lifestyle factors; and improving sleep quality and anxiety scores in stressed adults. It does not establish ashwagandha as a treatment for clinical anxiety disorders, and it should not be positioned as a replacement for therapy or evidence-based medications in clinical populations.

How stress depletes the body through the cortisol-magnesium-NAD+ cycle is explored in detail in this article — understanding that broader framework helps contextualize where ashwagandha fits in stress management.

Combining Ashwagandha with Magnesium for Anxiety

Magnesium and ashwagandha target anxiety through different mechanisms: magnesium works peripherally via NMDA receptor blockade and GABA-A potentiation, while ashwagandha works centrally on HPA axis reactivity. The two are mechanistically complementary rather than redundant. Several stress-management protocols combine both, and while no trial has directly tested the combination against either alone for anxiety, the mechanistic rationale is coherent.

Practically: magnesium deficiency is common in chronically stressed adults (cortisol drives urinary magnesium excretion), so addressing both the HPA axis dysregulation (ashwagandha) and the downstream magnesium depletion (magnesium glycinate) makes physiological sense. This overlap is covered in the ashwagandha vs. magnesium comparison.

Safety, Dosing, and Duration

Across published trials, KSM-66 ashwagandha root extract has a favorable safety profile at doses of 300–600 mg/day for durations up to 60–90 days. Reported adverse events are rare and mild: transient GI discomfort, loose stools, and drowsiness in some individuals (the drowsiness is consistent with its GABA-modulating mechanism and is dose-dependent). No clinically significant laboratory abnormalities have been reported in RCTs using root extracts.

The rare hepatotoxicity cases reported in the literature involved leaf-based extracts or high-dose concentrated preparations, not the root extracts used in the RCTs reviewed here. The distinction matters for safety assessment. Bio:sudo KSM-66 Reishi Restore uses standardized KSM-66 root extract at a clinically studied dose, consistent with the trial formulations.

Contraindications to be aware of: ashwagandha has mild thyroid-stimulating effects and should be used cautiously by individuals with hyperthyroidism or on thyroid medications. It may also potentiate sedative medications. Pregnancy and breastfeeding are contraindications given limited safety data in these populations.

Who Benefits Most

Based on the trial populations and effect sizes, the strongest evidence is for: adults aged 18–65 with high perceived stress from lifestyle factors (work, sleep deprivation, high-demand environments); people with elevated serum cortisol relative to their clinical baseline; individuals with stress-related sleep disruption, where the cortisol-reducing effect also improves sleep onset; and adults who have tried lifestyle interventions (exercise, sleep hygiene, stress reduction) but want adjunctive biochemical support for HPA axis regulation. The Wankhede et al. (2015) study also documented stress and recovery benefits in resistance-trained adults, suggesting the anxiolytic effects extend to exercise-induced physiological stress.

Practical Takeaways

• Multiple RCTs show KSM-66 ashwagandha at 300–600 mg/day reduces perceived stress scores and serum cortisol by 20–30% compared to placebo over 60–90 days
• The primary mechanism is HPA axis modulation — reducing the cortisol response to stress — with secondary GABA-A receptor activity contributing to anxiolytic and sleep effects
• Evidence applies specifically to standardized root extracts (KSM-66, Sensoril); generic root powder without withanolide standardization has a much weaker evidence base
• The evidence is for stressed healthy adults, not clinical anxiety disorder populations — scope your expectations accordingly
• Ashwagandha and magnesium are mechanistically complementary for stress and anxiety; combining them addresses both HPA axis reactivity and the downstream magnesium depletion that stress causes
• Bio:sudo KSM-66 Reishi Restore provides the standardized extract form used in positive clinical trials

Bottom Line

Ashwagandha for anxiety is one of the better-supported applications in the herbal supplement space — consistent cortisol reduction and anxiety score improvement across multiple independent RCTs, with a plausible mechanism and acceptable safety profile. The honest caveat is that the evidence is for stressed healthy adults, not clinical anxiety disorders, and most trial durations are 60–90 days. What happens beyond that window is not well characterized. For the right population and the right product form, this is a reasonable evidence-based intervention.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian J Psychol Med. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." J Int Soc Sports Nutr. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha root extract in improving memory and cognitive functions." J Dietary Suppl. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." J Altern Complement Med. 2014;20(12):901–908. [Source]

---

---